Focal segmental glomerulosclerosis N05.1

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 01.03.2021

Dieser Artikel auf Deutsch

Synonym(s)

Collapsing focal segmental glomerulosclerosis; Collapsing FSGS; Collapsing glomerulopathy; Focal and segmental glomerulosclerosis; focal segmental glomerulosclerosis; Focal segmental glomerulosclerosis; FSGS

Definition
This section has been translated automatically.

The term "focal segmental glomerulosclerosis" (FSGS) covers a group of serious, chronic kidney diseases that can occur in adolescence and also in adulthood. The diagnosis "FSGS" is a histological diagnosis. The FSGS is characterized by a loss of the podocyte processes of the renal glomeruli to varying degrees, by sclerosis of the capillary loops in the glomeruli (glomerulosclerosis) and clinically by a nephrotic syndrome of varying severity, possibly with acute consequences. If left untreated, the disease quickly leads to a loss of kidney function and to the need for dialysis.

Classification
This section has been translated automatically.

Primary (idiopathic) focal segmental glomerulosclerosis also known as collapsing focal segmental glomerulosclerosis (FSGS).

Familial or genetic forms of focal segmental glomerulosclerosis (FSGS), often steroid-resistant FSGS, especially when it occurs in children. Autosomal dominant inheritances with varying penetrance have been described, but autosomal recessive inheritances have also been described. Suspect gene loci have been identified on the following chromosomes:

  • Chromosome 1 (gene for podocin)
  • Chromosome 11 (gene for the TRPC6 calcium channel)
  • chromosome 14 (INF2 gene: encodes a protein that polymerizes and depolymerizes actin in the podocyte)
  • Chromosome 15 (MYO1E gene, encodes for myosin1E). Chromosome 19 (nephrin gene NPHS1; ACTN4 gene encoding protein actinin 4).
  • The genes identified so far encode proteins involved in glomerular basement membrane formation and/or podocyte differentiation and function: podocin, nephrin, alpha-actinin-4, TRPC6, CD2AP, inverted formin.

The following clinical syndromes have been identified to date and assigned to the Familial form of FSGS:

  • Familial autosomal dominant FSGS: a mutation of the ACTN4 gene (19q13), which encodes the actin-binding protein actinin 4 expressed in the podocyte, is present.
  • Familial autosomal dominant FSGS: a mutation of the TRPC6 gene, which encodes a calcium channel, is present. The gene mutation (so-called gain-of-function mutation) leads to calcium channel activation. As a result, both increased and decreased calcium influx via the TRPC6 protein into podocytes, can lead to FSGS.
  • Familial FSGS with present mutation in COL4A3-5 gene. Collagen IV mutations were detected in 38% of families in a larger study of familial FSGS (Gast C et al. 2015).
  • Congenital nephrotic syndrome which is inherited recessively. Present is a mutation of the NPHS2 gene (1q25-31), which encodes podocin. Podocin is expressed exclusively in podocytes and functions as a transmembrane connecting protein between the plasma membrane and the cytoskeleton.
  • Congenital nephrotic syndrome characterized by mutations in the CD2AP gene, which encodes the CD2 associated protein, a so-called slit membrane protein.
  • Steroid-resistant, autosomal recessive nephrotic syndrome characterized by a mutation in the NPHS2 gene (1q25-31), which encodes podocin, also a slit membrane protein. Mutations of NPHS2 are a common cause of steroid-resistant nephrotic syndrome (SRN) in childhood. Mutations in the NPHS2 gene can also be identified as a cause of nephrotic syndrome in adults.
  • Steroid-resistant autosomal recessive nephrotic syndrome characterized by a mutation in the NEIL gene, which encodes a DNA repair enzyme.
  • Steroid-resistant autosomal recessive nephrotic syndrome characterized by a mutation in the MYO1E gene (15q21), which codes for myosin1E, a so-called unconventional myosin (in contrast to the myosins found in muscle fibers, which are called class II or conventional myosins).
  • FSGS in Afro-Africans characterized by a mutation in the APOL1 gene, which encodes apolipoproteinL1.
  • Charcot-Marie-Tooth disease an autosomal dominantly inherited glomerulosclerosis characterized by a mutation in the INF2 gene, which encodes formin2. Formin2 plays a role in the organization of the actin filaments of the cytoskeleton and further in the response to DNA damage, and cellular stress.

Secondary (adaptive) FSGS: This term includes those forms of focal segmental glomerulosclerosis that are due to hypertrophy or hyperfiltration of the glomeruli as a result of previous renal damage that has either led to a relevant decrease in the total number of glomeruli, or has led to dilatation of the renal vessels with a constant number of glomeruli. The initial change is damage to the podocytes. Circulating cytokines (e.g. TGF-beta), inflammatory mediators or increased intravascular pressure within the glomerulus are discussed as causative factors. Due to a progressive destruction of the podocyte feet, the basement membrane is exposed. The filtration barrier formed by the so-called slit membrane of the podocytes becomes more permeable. Larger amounts of fluid and albumin are filtered. Macromolecules such as IgM, fibrinogen or complement components cannot pass the basement membrane. However, they are deposited as hyaline depots between the endothelium and the basement membrane. Causative diseases:

  • Dilatation of renal vessels (renal vasodilation) in: diabetic nephropathy, after renal transplantation (high recurrence rate - Gheith O et al 2013), in sickle cell disease and severe obesity. Glycogen storage diseases and pre-eclampsia can also lead to dilatation of renal vessels, increase in pressure in the glomerulus and thus secondary FSGS.
  • Healing phase after glomerulonephritis: FSGS may also occur in the healing phase of inflammatory renal diseases such as lupus nephritis, IgA nephritis and Rapid progressive glomerulonephritis. The cause may be the increased release of TGF-beta.
  • Heroin nephropathy: FSGS may occur in heroin addicts, especially those of black African descent. Heroin nephropathy can progress to chronic renal failure over a period of years, and thus progresses more slowly than HIV-associated FSGS (which can lead to renal failure within months).
  • Other secondary forms of FSGS: FSGS has been described in abusive use of anabolic steroids, after treatment with lithium, and in lymphoma disease.
  • Other causative drugs include: pamidronate, NSAIDs; anabolic steroids.
  • Virus-induced secondary FSGS (rather rare in children): HIV, parvovirus B19, CMV, EBV, HCV (Dettmar AK et al. 2016).

Occurrence/Epidemiology
This section has been translated automatically.

In Europe, FSGS is the cause of a nephrotic syndrome with 12% of the cases. In the U.S., FSGS is the most common primary glomerular disease leading to dialysis-related kidney failure.

Etiopathogenesis
This section has been translated automatically.

The causes of focal segmental glomerulosclerosis are manifold and ultimately unknown (Canaud G et al. 2016). It is possible that a previously unknown systemic permeability factor is the triggering factor. Congenital forms can be traced back to individual mutated podocyte proteins of the glomeruli (Rosenberg AZ et al. 2017).

Clinical features
This section has been translated automatically.

In the clinical picture the focal sclerosing glomerulonephritis is conspicuous by symptoms of the nephrotic syndrome:

  • nephrotic proteinuria: 60-75%
  • Micro-haematuria: 30-50
  • Renal hypertension: 45-65
  • Reduction of renal function: 25-50 %.
  • Also: hypalbuminaemia, hyperlipidaemia, edema, tendency to infections
  • In primary FSGS the soluble urokinase-plasminogen activator receptor (suPAR) is elevated in 65% of cases (see below plasminogen activator inhibitors). A lowering of the soluble receptor by plasmapheresis leads to remission of the disease.

Histology
This section has been translated automatically.

FSGS is characterized by segmental sclerosis of capillary loops in glomeruli (Nagata M et al. 2017). For histological reasons, several types with different courses and prognoses can be distinguished (Han MH et al. 2016):

  • Classical FSGS (FSGS, NOS, Not Otherwise Specified); most frequent type
  • Perihilar variant
  • Tip lesion (tip variant)
  • Collapsing glomerulopathy (collapsing variant)
  • Cell-rich variant (cellular variant): lesions (at the tubular pole)
  • C1q nephropathy (controversial variant)

Diagnosis
This section has been translated automatically.

The diagnosis is made by a kidney puncture. Since 2004 (Columbia Classification - see Han MH et al. 2016), several variants have been distinguished on the basis of fine tissue characteristics, which differ in their course and prognosis:

  • Classic FSGS: Light microscopic changes are detectable in some, but not in all glomeruli (focal). In the altered glomeruli, typically only some segments of the vascular cluster are affected (segmental). In the affected segments there is a collapse of the capillary loop, sclerosis and cell proliferation in the mesangium of the glomerulus. Due to the increased permeability of the capillary walls, plasma proteins are deposited in the capillary walls in the form of hyaline precipitates. Direct immunofluorescence (DIF) does not show specific deposits.
  • Collapsing glomerulopathy (Collapsing glomerulosclerosis): Common in people of black African descent. The entire capillary cluster of the glomerulus, not just individual segments (segmental), is collapsed and sclerosed. The cause is either idiopathic or caused by HIV infection. In most cases a severe nephrotic syndrome is clinically conspicuous. Renal function usually deteriorates rapidly (Fogo AB 2015; Raja R et al. 2016).
  • Tip variant: Beginning at the urinary pole (tip) of the glomerulus. Damage to epithelial cells and accumulation of fatty foam cells. IgM and complement component C3 can be detected immunohistologically. Clinically characteristic is an abrupt onset of a nephrotic syndrome. Therapeutically remarkable is the good response to corticosteroid therapy. Occasionally, spontaneous remissions are observed even without immunosuppressive therapy. Overall good prognosis.
  • Perihilar variant: Changes in the hilus of the glomerulus with sclerosis and deposition of transparent hyaline material in > 50 % of segmentally sclerosed glomeruli. Immunohistological and electron microscopic findings are detectable as in classic FSGS. The perihilar variant is frequently used in diseases that are associated with an overload of the glomerulus (hyperfiltration).
  • Cellular variant: Detection of at least one glomerulus with a segment in which the glomerular capillaries are closed by cell proliferation. In the remaining glomeruli, changes are found as in classic FSGS. Electron microscopy reveals diffuse fusion of the podocyte foot processes.
  • C1q-Nephropathy: Controversial diagnostic entity. Immunohistological detection of deposits of the complement component C1q in the capillaries of the glomerulus. Mainly in children and young adults. Poor response to immunosuppressive therapy. Spontaneous remissions with disappearance of C1q deposits are known.

Therapy
This section has been translated automatically.

General therapy of nephrotic syndrome (see there)

Untreated, patients with primary FSGS with nephrotic syndrome have a poor renal prognosis. Important prognostic factors are the extent of proteinuria, impaired renal function, histological characteristics and response to medium-dose steroid therapy (prednisolone 1mg/kgkgKG/day). Steroid resistance occurs if proteinuria persists after > 4 months of treatment with high-dose steroids. As alternatives to the therapy of primary FSGS calcineurin inhibitors, tacrolimus (Raja R et al. 2016), mycophenolate-mofetil (MMF), cyclophosphamide and rituximab (Kronbichler A et al. 2014) are available. Therapy of a relapse: renewed steroid cycle if necessary supplemented with an immunosuppressive agent(Ciclosporin A, mycophenolate-mofetil). Placebo-controlled studies on initial therapy of primary FSGS are currently lacking (Trachtman H 2017).

Progression/forecast
This section has been translated automatically.

Without remission, 50% of patients are terminally kidney insufficient after 10 years. With full remission the figure is only 10% (Cohen CD et al. 2017).

Note(s)
This section has been translated automatically.

The histological picture of FSGS is also perceived as "scarring" in the advanced stages of many glomerulopathies. It must then be separated clinically and histologically from the actual disease FSGS.

Literature
This section has been translated automatically.

  1. Meyrier A (2003) Treatment of idiopathic nephrosis by immunophillin modulation. Nephrol Dial Transplant 18 Suppl 6:vi79-86.
  2. Canaud G et al (2016) Recurrence of Focal and Segmental Glomerulosclerosis After Transplantation. Transplantation 100:284-287.
  3. Cohen CD et al (2017) Abnormal Kidney Function. In: Batteguay E (Ed.) Differential diagnosis of internal diseases. Thieme Publishing House Stuttgart, New York S. 465
  4. Dettmar AK et al (2016) Infection-Related Focal Segmental Glomerulosclerosis in Children. Biomed Res Int 2016:7351964.
  5. Fogo AB (2015) Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 11:76-87.
  6. Gast C et al (2015) Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol dial graft 31:961-970.
  7. Gheith O et al (2013) Focal segmental glomerulosclerosis and kidney transplantation. Iran J Kidney Dis 7:257-264.
  8. Han MH et al (2016) Practical Application of Columbia Classification for Focal Segmental Glomerulosclerosis.Biomed Res Int 2016: 9375753.
  9. Jefferson JA et al. (2014) The pathogenesis of focal segmental glomerulosclerosis. Adv Chronic Kidney Dis 21:408-416.
  10. Kronbichler A et al (2014) Rituximab in adult minimal change disease and focal segmental glomerulosclerosis. Nephron Clin Pract 128(3-4):277-282.
  11. Nagata M et al (2017) Focal segmental glomerulosclerosis; why does it occur segmentally? Pfluger's Arch 469(7-8):983-988.
  12. Raja R et al (2016) A prospective study of collapsing focal segmental glomerulosclerosis. Ren Fail 38:894-898.
  13. Rosenberg AZ et al (2017) Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 12:502-517.
  14. Trachtman H (2017) Investigational drugs in development for focal segmental glomerulosclerosis. Expert Opinion Investigational Drugs 26:945-952.

Incoming links (1)

Nephrotic syndrome;

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 01.03.2021